Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias

Fig. 3

Intention-to-treat survival curves of propensity score-matched idiopathic pulmonary fibrosis patients who were or were not treated with antifibrotics. (A) The nintedanib-exposed group had a significantly higher survival rate than the unexposed group (HR, 0.74; 95% CI, 0.68–0.80; p < 0.0001). The median survival times of the nintedanib-exposed and unexposed groups were 38.7 and 34.6 months, respectively. (B) The pirfenidone-exposed group had a significantly higher survival rate than the unexposed group (HR, 0.86; 95% CI, 0.81–0.92; p < 0.0001). The median survival times of the pirfenidone-exposed and unexposed groups were 34.7 and 31.6 months, respectively. HR, hazard ratio; CI, confidence interval

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us